Maria Soroka‐Wojtaszko

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 327 citations

Polycythaemia Vera, Hematology, Clinical Trials +5

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Marek Hus, Anna Dmoszyńska, Maria Soroka‐Wojtaszko et al. · PubMed · 2001 · 85 citations

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa et al. · The Lancet · 2023 · 77 citations · Full text

Thrombopoiesis, Autoimmune Disease, Blood Platelet +11

Production of Proangiogenic Cytokines During Thalidomide Treatment of Multiple Myeloma

Anna Dmoszyńska, Agnieszka Bojarska−Junak, Damian Domański et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2002 · 37 citations

Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts.

Norbert Grząśko, Anna Dmoszyńska, Marek Hus et al. · PubMed · 2006 · 11 citations

Hematological Malignancy, Tumor Necrosis Factor, Thalidomide Treatment +12